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Received March 25, 2014; accepted January 11, 2015AbstractBackground: The neurobiological basis of autism remains poorly understood. We hypothesized that endothelial antibodies may be associated
with the pathophysiology of autism and may predict intellectual/social developmental abnormalities.
Methods: Plasma levels of antiendothelial cell antibodies (AECAs) were measured by enzyme-linked immunosorbent assay in autistic children
(n ¼ 55) and age-matched healthy controls (n ¼ 25).
Results: The serum level of AECAs in children with autism {n ¼ 55, 306.4 ± 45.6 pg/mL [mean ± standard error of the mean (SEM)]} was
higher (two-tailed Student t test: p ¼ 0.05) than that of healthy controls [n ¼ 25, 209.6 ± 24.6 pg/mL (mean ± SEM)]. Children with severe
autism exhibited significantly higher AECAs than healthy controls (diagnoses of autistic children based on the Childhood Autism Rating Scale
score, >40) [n ¼ 20, 369.6 ± 65.6 pg/mL (mean ± SEM)] ( p ¼ 0.03). Disease severity and the Childhood Autism Rating Scale score, which
represent stereotyped patterns of behavior in children with autism, were positively correlated (r2 ¼ 0.27, p ¼ 0.05).
Conclusion: Elevated AECA serum levels may be implicated in the pathogenesis of autism. However, these data should be interpreted with
caution until further investigations are performed using larger sample sizes to determine whether the increase in serum AECA levels is a mere
consequence of autism or it plays a pathogenic role in the disease.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: antiendothelial antibodies; autistic spectrum disorder; autoimmunity; biomarker1. Introduction
Children with autism exhibit marked deficits in interper-
sonal social behaviors, abnormal language development,
restricted interests, stereotypic/ritualistic behaviors that
accompany a particular developmental course, and evidence of
developmental delay within the first 3 years of life.1e4Conflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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http://dx.doi.org/10.1016/j.jcma.2015.01.008
1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical AssAutoimmunity to the central nervous system may play a
pathogenic role in autism spectrum disorder (ASD).5e7
Recently, two lines of research have focused on biological
factors in autism. First, excesses of neurotrophins and neuro-
peptides in infant sera have a predictive value in determining
those children who later exhibit disruption of intellectual and
or social development.6 We have established that one of these
factors, brain-derived neurotrophic factor, is elevated in chil-
dren with autism.8 Second, autoantibodies to several antigenic
targets are present in the sera of some children with neuro-
developmental disorders.9,10 These facts have led us to search
for biological markers that may allow earlier detection of
autism. In this study, we determined the serum levels of
antiendothelial cell antibodies (AECAs) in a group of well-ociation. All rights reserved.
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group.
AECAs are observed in various autoimmune diseases,
including systemic lupus erythematosus, scleroderma, mixed
connective tissue diseases, hemolytic uremic syndrome, Sjog-
ren's syndrome, rheumatoid arthritis, vasculitis, lupus nephritis,
Kawasaki disease, and progressive systemic sclerosis.11e15
However, serum levels of endothelial cells in patients with
autism have never been reported. Thus, the aim of this study
was to explore a possible role for AECAs in patients with ASD.
2. Methods2.1. ParticipantsThis caseecontrol study was conducted with 55 children
with classic-onset autism. The autistic group consisted of 47
males and eight females. The children were recruited from the
Autism Research and Treatment Center, Faculty of Medicine,
King Saud University, Riyadh, Saudi Arabia. Their ages
ranged between 3 years and 12 years
(mean ± SD ¼ 7.98 ± 2.59 years). The patients fulfilled the
criteria for the diagnosis of autism according to the fourth
edition of the Diagnostic and Statistical Manual of Mental
Disorders.1 We excluded patients with associated neurological
diseases (such as cerebral palsy and tuberous sclerosis) or
associated metabolic disorders (e.g., phenylketonuria) because
the association of these comorbidities with autism may influ-
ence AECA levels. Patients were not receiving any
medications.
The control group consisted of 25 age- and sex-matched
healthy children (21 males and 4 females). The children's
ages ranged between 4 years and 12 years
(mean ± SD ¼ 8.79 ± 2.89 years). The children were the
healthy older siblings of healthy children who attend the Well
Baby Clinic, King Khalid University Hospital, Faculty of
Medicine, King Saud University, for routine follow-up of their
growth parameters. In addition, informed written consent for
participation in the study was given by the parents or legal
guardians of the participants.2.2. Study measurementsClinical evaluation of autistic patients was based on clinical
histories provided by caregivers, clinical examinations, and
neuropsychiatric assessments. In addition, the degree of
autism severity was assessed using the Childhood Autism
Rating Scale (CARS),16 which rates the child on a scale from
one to four in each of 15 areas (relating to people; emotional
response; imitation; body use; object use; listening response;
fear or nervousness; verbal and nonverbal communication;
activity level; level and consistency of intellectual response;
adaptation to change; visual response; taste, smell, and touch
response; and general impressions). According to the scale,
children who score 30e36 have mild to moderate autism
(n ¼ 35), whereas those with scores ranging between 37 points
and 60 points have severe autism (n ¼ 20).2.3. Blood samplesAfter overnight fasting, blood samples (3 mL) were
collected from participants of both groups in plain test tubes.
Blood samples were allowed to clot and were then centrifuged
at 3000 rpm to collect serum samples, which were stored in a
freezer at 80C until they were analytically assayed. A
detailed description of the procedure has been provided in our
previous reports.3,17 To increase accuracy, all samples were
analyzed twice in two independent experiments to assess
interassay variations and ensure the reproducibility of the
observed results ( p > 0.05).2.4. Assessment of serum AECAsLevels of AECAs were measured using a commercially
available sandwich enzyme immunoassay (enzyme-linked
immunosorbent assay) kit from Cusabio Biotech Co., Ltd
(Wuhan, China). No significant cross-reactivity or interference
was observed.2.5. Statistical analysisThe results were analyzed using the commercially available
software package Statview (Abacus Concepts, Inc., Berkley,
CA, USA). The data are presented as the mean ± standard
error of the mean (SEM). The ManneWhitney U test was used
for comparisons between data. Spearman's rank correlation
coefficient “r” was used to determine the relationship between
variables. For all tests, p < 0.05 was considered significant.
The receiver operating characteristic curve is a plot of sensi-
tivity versus 1-specificity at different cutoff values of the
studied variable. The uppermost left point represents the best
cutoff value (based on the highest sensitivity with the lowest
false-positive results of the studied marker) to differentiate
between the two groups under study. If the area under the
curve is > 0.5, the variable is able to differentiate between the
two groups; the closer this area to 1, the better its differenti-
ating capacity. The best cutoff value of serum AECAs was
254 pg/mL, with the area under the curve being 0.64, indi-
cating that plasma AECA was a good differentiating marker
between patients and controls at this cutoff value.
3. Results
The general characteristics of the study participants and the
results of the AECA levels are depicted in Table 1. Patients
exhibited significantly higher serum AECA levels [n ¼ 55,
306.4 ± 45.6 pg/mL (mean ± SEM)] ( p ¼ 0.05, Fig. 1) than
did normal controls [n ¼ 25, 209.6 ± 24.6 pg/mL
(mean ± SEM)]. Increased serum AECA levels were observed
in 63% (41/55) of autistic children.
There was a significant difference between normal controls
and patients with severe autism (autism diagnoses made on the
bases of CARS scores of >40) [n ¼ 20, 369.6 ± 65.6 pg/mL
(mean ± SEM)] ( p ¼ 0.03). However, there was no significant
difference between the serum AECA levels of children with
Table 1
Serum levels of AECAs in autistic children and their relationship with autism
severity.
AECAs (pg/mL) p
Healthy children (n ¼ 25) 209 ± 24.6
Patients with autism (n ¼ 55) 306.4 ± 45.6 <0.05
Patients with mild to moderate autism (n ¼ 35) 270 ± 61
Patients with severe autism (n ¼ 20) 369.6 ± 65.6 <0.03





























Fig. 2. Serum levels of AECA in controls and autistic children (mild to
moderate and severe conditions based on the CARS score).
AECA ¼ antiendothelial cell antibody; CARS ¼ Childhood Autism Rating
Scale.
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( p ¼ 0.16; Fig. 2).
There was a positive correlation between disease severity
and the CARS score, which represents stereotyped patterns of
behavior in children with autism (r2 ¼ 0.27, p ¼ 0.05; Fig. 3).
There was no significant difference between the serum
AECAs of male and female autistic patients ( p ¼ 0.72).
Serum AECA levels of autistic patients exhibited no signifi-
cant correlations with the ages of autistic children ( p ¼ 0.64).
4. Discussion
We observed significantly elevated AECA serum levels in
autistic children compared with a control group of healthy
children. Although caution should be exercised in the inter-
pretation of our data, our results suggest a potential role for
AECAs in this neurodevelopmental disorder.
Studies have identified autoantibodies to endothelial cells
and nuclei in children with autism, idiopathic mental retar-
dation, and epilepsy, but not in healthy control individuals or
those with non-neurologic diseases.18e22 Several immunologic
studies report T-cell dysfunction or abnormal numbers of T-
cells in a proportion of autistic patients.6,21e23
In some studies, autoantibodies are not specific to autism.
For example, Todd et al24 observed antibrain IgG autoanti-
bodies, determined by dot blot analysis, that were nonspecific
and present in sera from both normal individuals and























Fig. 1. Serum levels of endothelial proteins in controls and autistic children.
Differences in anti-endothelial cell serum antibody levels between autistic
children and healthy controls were statistically significant ( p ¼ 0.05).
AECA ¼ antiendothelial cell antibody.cell activation is defined as “quantitative changes” in the
expression levels of specific gene products (i.e., proteins),
which in turn endow endothelial cells with new functional
capacities. Endothelial cell antigens can be constitutively
expressed and/or modulated by either cytokines or cryptic
means. In addition, antigen determinants for AECAs may also
include molecules that adhere to the endothelium. An alter-
native mechanism by which AECAs could act as a trigger in
the pathogenesis of some diseases may involve complement
cytotoxicity and/or antibody-dependent cellular
cytotoxicity.26e29
In this study, we measured high mean AECAs in the sera of
children with autism compared with healthy controls. Some
investigators have reported that endothelial cell activation can
be induced by AECAs. Phenotypic changes in the endothelium
can be due, in part, to the induction of interleukin (IL)-1
synthesis or other mediators (i.e., IL-1, IL-2, IL-4, IL-6, IL-8,
and Macrophage Inflammatory Proteins (MIP)-1).30
There may be a variety of autoantibodies in individuals
with autism. The presence of these autoantibodies may be a
secondary marker of disease rather than directly pathogenic.Fig. 3. Relationship between the serum levels of AECA in autistic children and
the CARS score. AECA ¼ antiendothelial cell antibody; CARS ¼ Childhood
Autism Rating Scale.
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antibodies in a large cohort of children. Irrespective of
whether these autoantibodies are of direct etiological rele-
vance, the presence of a marker of disease in ASDs may be
important to help determine the time of onset of these
devastating disorders. Other autoimmune diseases have both
specific and nonspecific autoantibodies.
The chief caveats of our report are the small sample size
and its cross-sectional design. We were only able to observe
associations, not predictions or causation. Another limitation
of our report is that adaptive behavior was not assessed in the
control individuals. Therefore, whether levels of AECA fac-
tors may be associated with behavioral features in healthy
individuals remains to be established. These caveats notwith-
standing, we have demonstrated an alteration of the endothe-
lial cell environment in autism characterized by a clear
imbalance of important AECAs.
The knowledge resulting from autoimmunity research has
direct clinical relevance to the overall health and recovery of
autistic children. Our findings provide preliminary, direct ev-
idence of altered AECAs in patients with ASD, which may
contribute to the early pathogenesis of ASD, offer valuable
biomarkers, point to novel therapeutic development for
autism, and offer a novel approach to immunotherapy with the
use of natural immunomodulators.
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